TUCSON, AZ – UGenome AI, a pioneer in genomic technology, today announced an expanded partnership with Jura Health, Inc. to integrate both pharmacogenomic and nutrigenomic insights into the diagnosis of rare diseases and the development of personalized care plans. By combining expertise in whole genome sequencing (WGS), drug-gene interactions, and nutrient- gene relationships, the collaboration is designed to help rare disease patients receive earlier diagnoses, safer treatments, and lifestyle guidance tailored to their DNA.Continue reading
Category Archives: AZBio News
Critical Path Institute and Citizen Health Partner to Accelerate Drug Development for Neuromuscular Disorders
SAN FRANCISCO and TUCSON, Ariz., May 29, 2025 — Critical Path Institute® (C-Path), a global nonprofit accelerating drug development through data science and regulatory innovation, and Citizen Health, a leading consumer health platform, today announced their new strategic collaboration. Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.Continue reading
CEO Forums: An FDA Listening Tour to Engage Pharma CEOs
The U.S. Food and Drug Administration is conducting a national listening tour to meet directly with pharmaceutical and biotech CEOs. Held in major innovation hubs across the country, the CEO Forums will be led by FDA Commissioner Marty A. Makary, M.D., M.P.H., along with Principal Deputy Commissioner Sara Brenner, M.D., M.P.H and Director of FDA’s Center for Biologics Evaluation and Research, Vinay Prasad, M.D., M.P.H.Continue reading
ASU partners with biotech luminary and alum Mark McKenna to launch preeminent life science business program
- Future health care leaders and innovators will accelerate their path through the McKenna Life Sciences, Business and Entrepreneurship Program, enabling the next generation of biotech game changers.
- A cross-college collaboration between the W. P. Carey School of Business and The College of Liberal Arts and Sciences, the program reflects ASU’s decade-long status as America’s most innovative university.
- The program will launch in 2026 through a generous gift from Mark and Sheri McKenna.
Drug discovery startup based on UA research receives $4 million seed funding
The preclinical stage company was founded to commercialize drugs to treat multiple cancers.Continue reading
BIO Announces Dedicated Focus on Human Health and Biopharmaceutical Innovation
- BIO to Transition Agricultural and Environmental Biotech Workstreams
- Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies
and Economic Growth
Study says original COVID-19 vaccination did not stop immune system from fighting variants
- Vaccinated people generated an overall protective immune response to the Delta and Omicron strains of COVID-19, though with slightly fewer antibodies for the mutated parts of the virus.
- University of Arizona Health Sciences researchers found that people who received the original COVID-19 vaccine had greater antibody production against the Delta and Omicron variants than those who were unvaccinated.
- Prior COVID-19 vaccination did not stop the immune system from mounting a protective response to the Delta and Omicron strains, though new mutation-specific antibody production dipped slightly, according to a study led by researchers at the University of Arizona Health Sciences and published in Nature Immunology.
Study reveals weakness in rare ovarian cancer tumors that may lead to improved treatment options
Findings could suggest new targets for immunotherapy
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
Cargill’s Bioindustrial business Partners with Arizona State University to Explore New Materials for Semiconductor Innovation
TEMPE, Ariz. (May 15, 2025) — Cargill Bioindustrial and Arizona State University (ASU) are launching a new, year-long research partnership focused on advanced materials used in semiconductor technology — the foundation of modern electronics from smartphones to electric vehicles.
The research is focused on Cargill™ Priamine™ dimer diamine, which is made from bio-based ingredients. With support from ASU’s Biodesign Institute, scientists will study how and why this material performs so well, and how it might be used to improve the speed, efficiency, and reliability of electronic devices.Continue reading